Triplet Therapeutics – Developing Treatment for Huntington’s Disease
Triplet Therapeutics is working on somatic instability as a way of possibly treating Huntingon’s Disease (HD)
During this video, we asked Nessan Bermingham, Brian Bettencourt, Irina Antonijevic & Dr. Anne Rosser about Triplet’s mission and their new approach. They also introduced Triplet’s natural history study of Huntington’s disease, called SHIELD HD.
About the Phase I/II Clinical Program of AMT-130
This HD clinical trial will explore the safety, tolerability, and efficacy signals in 26 total patients with early manifest HD. “We are very pleased with the progress that we continue to make in this Phase 1-2 clinical trial and that we are now administering AMT-130 at the higher dose,” said Ricardo Dolmetsch, Ph.D., president of research at uniQure.
Scientists identify precisely how pridopidine works in models of Huntington’s disease.
Pridopidine is a drug developed to treat Huntington’s disease (HD) and now scientists have a clearer understanding of how it works in the body and brain.